Sanofi backs Altesa's $75M series B to bankroll antiviral's midstage rhinovirus study
Sanofi backs Altesa's $75M series B to bankroll antiviral's midstage rhinovirus study
Sanofi backs Altesa's $75M series B to bankroll antiviral's midstage rhinovirus study
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.